Abstract
The translational stem cell research field has progressed immensely in the past decade. Development and refinement of differentiation protocols now allows the generation of a range of cell types, such as pancreatic β-cells and dopaminergic neurons, from human pluripotent stem cells (hPSCs) in an efficient and good manufacturing practice-compliant fashion. This has led to the initiation of several clinical trials using hPSC-derived cells to replace lost or dysfunctional cells, demonstrating evidence of both safety and efficacy. Here, we highlight successes from some of the hPSC-based trials reporting early signs of efficacy and discuss common challenges in clinical translation of cell therapies.
Original language | English |
---|---|
Article number | dev202067 |
Journal | Development (Cambridge, England) |
Volume | 151 |
Issue number | 7 |
Number of pages | 9 |
ISSN | 0950-1991 |
DOIs | |
Publication status | Published - 2024 |
Bibliographical note
© 2024. Published by The Company of Biologists Ltd.Keywords
- Humans
- Pluripotent Stem Cells
- Cell Line
- Cell Differentiation
- Cell- and Tissue-Based Therapy
- Stem Cell Research